Trial Profile
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia Phase 3
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
- 30 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 20 Mar 2014 New trial record